Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) 
- The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Overview 6
Therapeutics Development 7
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Stage of Development 7
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Therapy Area 8
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Indication 9
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Companies 12
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development 21
AbbVie Inc 21
Alkermes Plc 22
APT Therapeutics, Inc. 23
Mabtech Limited 24
Philogen S.p.A. 25
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles 26
ALKS-4230 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
APT-602 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
basiliximab - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
basiliximab biobetter - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
daclizumab - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Darleukin - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Recombinant Protein to Agonize IL2RA, IL2RB and IL2RG for Autoimmune Diseases - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Projects 40
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Featured News & Press Releases 42
Sep 15, 2016: New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA (Daclizumab) and Support Long-Term Safety Profile 42
Sep 08, 2016: Biogen Demonstrates Data on ZINBRYTA at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis 44
Aug 15, 2016: Diplomat to Dispense ZINBRYTA for the Treatment of Multiple Sclerosis 45
Jul 05, 2016: Biogen and AbbVie's Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis 45
May 27, 2016: Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosi 47
May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 48
Apr 29, 2016: Biogen and Abbvie Receive Positive Opinion From The CHMP on ZINBRYTA (daclizumab) For Treatment Of Multiple Sclerosis 49
Apr 22, 2016: Daclizumab Demonstrates Significant, Sustained Improvements In Cognition Compared To Interferon Beta-1A IM 50
Apr 20, 2016: Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action 51
Apr 12, 2016: Biogen to Present Data on ZINBRYTA at 2016 AAN Annual Meeting 53
Jan 21, 2016: Philogen Announces Commencement of Phase III Pivotal Trial in Melanoma 53
Oct 20, 2015: Results Published from a Phase 3 Trial of Daclizumab High-Yield Process (DAC HYP) in Relapsing MS 54
Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS 55
Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress 58
Apr 29, 2015: FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by AbbVie Inc, H2 2016 21
Pipeline by Alkermes Plc, H2 2016 22
Pipeline by APT Therapeutics, Inc., H2 2016 23
Pipeline by Mabtech Limited, H2 2016 24
Pipeline by Philogen S.p.A., H2 2016 25
Dormant Projects, H2 2016 40
Dormant Projects (Contd..1), H2 2016 41